Companion Diagnostics for Cancer and Autoimmune Drugs

Stratify patients based on autoantibody profiles detected using our KREX technology into responders, non-responders and those presenting with ADRs. This can enable delivery of the right treatment to the right patient at the right time as well as guiding strategies for improving drug efficacy, safety and reduction of ADRs.


Sengenics offers KREX for use in the discovery, validation, screening and development of new therapeutics through the use of discovery based KREX-based platforms.

Autoantibody-based Precision Immuno-Profiling and Therapeutics

Discover novel autoantibody biomarkers for early diagnosis of cancers, autoimmune and neurodegenerative diseases. Some of these autoantibodies are protective and may be in themselves be developed into actual therapeutic biomolecules.

Drug Discovery

The inactivation of p53 is widely established as a key feature in most cancers. Restoring the function of clinically significant p53 mutant proteins has become a major therapeutic target for cancer therapy. The OncoREX p53 cancer array has 100 functional p53 variants available for screening of small molecules to discover drugs that may target p53.

Custom Arrays

We have a library of 1000s of Human, Viral and Bacterial proteins, all expressed using our novel KREX technology. These proteins are correctly folded and functionally validated. Custom arrays for any number of proteins, in any format can be manufactured for high-throughput screening and validation studies.


High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389